Zoetis Inc. (ZTS): Price and Financial Metrics


Zoetis Inc. (ZTS): $201.95

-0.01 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZTS POWR Grades


  • Quality is the dimension where ZTS ranks best; there it ranks ahead of 95.92% of US stocks.
  • ZTS's strongest trending metric is Quality; it's been moving up over the last 161 days.
  • ZTS's current lowest rank is in the Momentum metric (where it is better than 15.77% of US stocks).

ZTS Stock Summary

  • With a market capitalization of $95,902,604,119, Zoetis Inc has a greater market value than 97.3% of US stocks.
  • With a one year PEG ratio of 278.29, Zoetis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.58% of US stocks.
  • Price to trailing twelve month operating cash flow for ZTS is currently 42.59, higher than 89.63% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to ZTS, based on their financial statements, market capitalization, and price volatility, are SYK, MMM, TFC, MDLZ, and PNC.
  • ZTS's SEC filings can be seen here. And to visit Zoetis Inc's official web site, go to www.zoetis.com.

ZTS Valuation Summary

  • In comparison to the median Healthcare stock, ZTS's EV/EBIT ratio is 33.45% higher, now standing at 39.1.
  • ZTS's price/sales ratio has moved up 9.4 over the prior 104 months.
  • Over the past 104 months, ZTS's price/earnings ratio has gone down 12.5.

Below are key valuation metrics over time for ZTS.

Stock Date P/S P/B P/E EV/EBIT
ZTS 2021-08-31 13.1 22.3 50.8 39.1
ZTS 2021-08-30 13.2 22.4 51.1 39.3
ZTS 2021-08-27 13.0 22.2 50.6 38.9
ZTS 2021-08-26 13.0 22.2 50.7 39.0
ZTS 2021-08-25 13.1 22.3 50.8 39.0
ZTS 2021-08-24 13.1 22.3 50.9 39.1

ZTS Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 326.19%.
  • Its year over year net income to common stockholders growth rate is now at 10.12%.
  • Its 5 year price growth rate is now at 165.5%.
ZTS's revenue has moved up $2,492,000,000 over the prior 49 months.

The table below shows ZTS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 7,616 2,252 1,982
2021-06-30 7,412 2,161 1,909
2021-03-31 7,012 2,118 1,774
2020-12-31 6,675 2,126 1,638
2020-09-30 6,542 1,990 1,663
2020-06-30 6,340 1,934 1,617

ZTS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZTS has a Quality Grade of A, ranking ahead of 95.14% of graded US stocks.
  • ZTS's asset turnover comes in at 0.552 -- ranking 69th of 682 Pharmaceutical Products stocks.
  • UTHR, ENDP, and MYGN are the stocks whose asset turnover ratios are most correlated with ZTS.

The table below shows ZTS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.552 0.697 0.236
2021-06-30 0.537 0.695 0.233
2021-03-31 0.518 0.694 0.219
2020-12-31 0.514 0.692 0.206
2020-09-30 0.525 0.696 0.212
2020-06-30 0.535 0.697 0.207

ZTS Price Target

For more insight on analysts targets of ZTS, see our ZTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $185.00 Average Broker Recommendation 1.34 (Strong Buy)

ZTS Stock Price Chart Interactive Chart >

Price chart for ZTS

ZTS Price/Volume Stats

Current price $201.95 52-week high $249.27
Prev. close $201.96 52-week low $141.41
Day low $200.28 Volume 761,798
Day high $203.71 Avg. volume 2,655,503
50-day MA $224.14 Dividend yield 0.64%
200-day MA $200.24 Market Cap 95.55B

Zoetis Inc. (ZTS) Company Bio


Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets the products in approximately 45 countries, and sells the products in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. (Source:Wikipedia)


ZTS Latest News Stream


Event/Time News Detail
Loading, please wait...

ZTS Latest Social Stream


Loading social stream, please wait...

View Full ZTS Social Stream

Latest ZTS News From Around the Web

Below are the latest news stories about Zoetis Inc that investors may wish to consider to help them evaluate ZTS as an investment opportunity.

7 of the Top-Rated Pharmaceutical Stocks for Q1

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | January 18, 2022

Apella Capital, LLC Buys Vanguard Ultra-Short Bond ETF, iShares MSCI Emerging Markets ex China ...

Investment company Apella Capital, LLC (Current Portfolio) buys Vanguard Ultra-Short Bond ETF, iShares MSCI Emerging Markets ex China ETF, Invesco BulletShares 2030 Corporate Bond ETF, FactSet Research Systems Inc, Costco Wholesale Corp, sells Dimensional U.S.

Yahoo | January 18, 2022

Zoetis Has A Giant Upcoming Dividend Increase

Dividend increases are an outward sign from management that the business is going well, and the company can increasingly reward shareholders. I track upcoming dividend increases from companies with a history of increasing them. The lists below contain different data points for the stocks increasing their dividends next week. This...

Dividend Derek on Seeking Alpha | January 14, 2022

FDA Approves Zoetis'' Solensia To Control Osteoarthritis Pain In Cats

The FDA has approved Zoetis Inc''s (NYSE: ZTS ) Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort, and overall well-being. Solensia, prescribed as a once-monthly injection administered in the veterinary clinic, controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain. The Full story available on Benzinga.com

Benzinga | January 14, 2022

Garrett Investment Advisors LLC Buys Vanguard Total Stock Market ETF, Vanguard FTSE Developed ...

Investment company Garrett Investment Advisors LLC (Current Portfolio) buys Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, iShares Core S&P 500 ETF, SPDR Portfolio Intermediate Term Treasury ETF, SPDR Portfolio S&P 500 Growth ETF, sells BTC iShares MSCI USA Momentum Factor ETF, Vanguard Dividend Appreciation FTF, Vanguard Small Cap ETF, JPMorgan Ultra-Short Income ETF, SPDR SSgA Ultra Short Term Bond ETF during the 3-months ended 2021Q4, according to the most recent filing

Yahoo | January 14, 2022

Read More 'ZTS' Stories Here

ZTS Price Returns

1-mo -16.27%
3-mo -2.87%
6-mo -0.53%
1-year 23.48%
3-year 144.32%
5-year 285.71%
YTD -17.11%
2021 48.26%
2020 25.76%
2019 55.71%
2018 19.45%
2017 35.55%

ZTS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ZTS Dividend History

Continue Researching ZTS

Here are a few links from around the web to help you further your research on Zoetis Inc's stock as an investment opportunity:

Zoetis Inc (ZTS) Stock Price | Nasdaq
Zoetis Inc (ZTS) Stock Quote, History and News - Yahoo Finance
Zoetis Inc (ZTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9091 seconds.